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Abstract: The central nervous system (CNS) may be considered as a sanctuary site, protected
from systemic chemotherapy by the meninges, the cerebrospinal fluid (CSF) and the blood-brain
barrier (BBB). Consequently, parenchymal and CSF exposure of most antineoplastic agents following
intravenous (IV) administration is lower than systemic exposure. In this review, we describe the
different strategies developed to improve delivery of antineoplastic agents into the brain in primary
and metastatic CNS tumors. We observed that several methods, such as BBB disruption (BBBD),
intra-arterial (IA) and intracavitary chemotherapy, are not routinely used because of their invasiveness
and potentially serious adverse effects. Conversely, intrathecal (IT) chemotherapy has been safely and
widely practiced in the treatment of pediatric primary and metastatic tumors, replacing the neurotoxic
cranial irradiation for the treatment of childhood lymphoma and acute lymphoblastic leukemia
(ALL). IT chemotherapy may be achieved through lumbar puncture (LP) or across the Ommaya
intraventricular reservoir, which are both described in this review. Additionally, we overviewed
pharmacokinetics and toxic aspects of the main IT antineoplastic drugs employed for primary or
metastatic childhood CNS tumors (such as methotrexate, cytosine arabinoside, hydrocortisone),
with a concise focus on new and less used IT antineoplastic agents.
Keywords: cerebrospinal fluid (CSF); blood-brain barrier (BBB); intrathecal (IT) chemotherapy;
lumbar puncture (LP); Ommaya reservoir; personalized medicine
1. Introduction
Childhood cancers include many malignancies that also occur in adults, such as acute lymphoblastic
leukemia (ALL) which is by far the most common, followed by central nervous system (CNS) tumors,
lymphomas and certain bone cancers (osteosarcoma and Ewing sarcoma). Cancers that are exclusive to
children include neuroblastoma, Wilms tumor, rhabdomyosarcoma, and retinoblastoma. Improvements
in the treatment of the childhood cancers have positively influenced overall disease-free survival, such
as in ALL [1]. “CNS prophylaxis” with repeated cycles of intrathecal (IT) methotrexate (MTX) has
replaced CNS prophylactic irradiation in children with low risk ALL, drastically reducing the incidence
of CNS relapse from 50% to 23% [2,3].
“CNS prophylaxis” for pediatric ALL derived from the recognition of CNS as a sanctuary site
protected from the systemic chemotherapy by the meninges, the cerebrospinal fluid (CSF) and the
blood-brain barrier (BBB) [4,5].
For most antineoplastic agents, the total CSF exposure following administration of a systemic
dose is less than 10% of the systemic exposure, as shown in Table 1. Consequently, IV administered
chemotherapy is usually not very efficacious in primary and metastatic CNS tumors. [6].
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Table 1. CNS penetration of commonly used anticancer drugs (adapted from Kerr et al. [6]).
Agent CSF: Plasma Ratio (%)
Thiotepa >95
Carmustine >90
Cyclophosphamide
Total drug 50
Active metabolite 15
Cisplatinum
Free platinum 40
Total platinum <5
Ifosfamide
Total drug 30
Active metabolite 15
Carboplatinum
Free platinum 30
Total platinum <5
6-Mercaptopurine 25
Cytarabine 15
Desametasone 15
Irinotecan
CPT–11 lactone 14
SN–38 lactone <8
Prednisolone <10
Vinca alkaloids 5
Topotecan <5
Methotrexate 3
L-asparaginase Nd
Anthracyclines Nd
D-Actinomycin Nd
Nd = Not detectable.
In this review, we summarize the principal aspects of physical and biochemical protection of
the brain, describing the several alternative strategies experimented during time to improve brain
delivery of chemotherapy in primary or metastatic childhood CNS tumors (low and high- grade glioma,
medulloblastoma, ependymoma, metastatic ALL and lymphoma), such as BBB disruption, intra-arterial
(IA), intracavitary and IT chemotherapy. Moreover, we provided an overview of pharmacokinetics
and toxic aspects of IT antineoplastic agents commonly used in pediatric oncology for primary or
metastatic CNS tumors.
2. Physical Protection of the Brain: Meninges and CSF
The human brain is soft and physically protected by bones of the skull, the meninges and the
CSF. The meninges present three layers in children and adults: the dura mater, the arachnoid and
the pia mater [7]. The dura mater is tough, strong and composed of fibrous connective tissue. The
arachnoid is a middle meninx that forms a loose brain covering; below the arachnoid there is a wide
subarachnoid space filled with CSF and large blood vessels. The pia mater is a deep meninx composed
of delicate connective tissue on the brain surface [8]. Usually considered as protective membranes, the
meninges play a prominent role in the development and maintenance of the CNS. They differentiate
at the third month of intrauterine life, playing a role in ontogenesis, by inducing proliferation and
differentiation of neuroblasts and axonal growth. Moreover, they are in constant evolution from their
formation to senescence.
The CSF is a clear liquid, similar in composition to blood plasma, without blood cells and with
less protein and different ion concentration than plasma. In fact, CSF is composed of water for 99%,
compared to the 92% of plasma. It is lower than plasma in protein, K+ and urea, but is higher in Na+,
Mg++ and Cl− concentration. The mean CSF volume is 150 mL in adults, with 25 mL in the ventricles
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and 125 mL in subarachnoid spaces, but with marked interindividual variations [9]. Gur et al. reported
that CSF volume is 164.5 ± 47.8 mL in adults, with 31.9 ± 17.8 mL in the ventricles, 0.95 ± 0.62 in the
third ventricle and 132.6 ± 43.2 mL in extraventricular spaces [10].
CFS serves two purposes: physical protection of the neuraxis and a chemical role in the homeostasis
of cerebral interstitial fluid and neuronal environment. The buoyancy of the CSF reduces the weight of
the brain, preventing the brain from crushing under its weight. It forms a liquid cushion that assures
hydro-mechanical protection of the CNS from blows and trauma. CSF also plays a prominent role in
brain development, by regulation of the brain interstitial fluid homeostasis, the electrolyte balance, the
circulation of active molecules and elimination of catabolites [11].
CSF secretion in adult varies from 400 to 600 mL/day, at approximately 25 mL/h. It is predominantly,
but not exclusively, secreted by the choroid plexuses inside the ventricles, under neuroendocrine
and hormonal modulation. A minimal poorly defined role in the CSF secretion is also played by the
extrachoroidal secretion, derived from the ependymal epithelium, from the extracellular fluid and the
cerebral capillaries across the blood-brain barrier [12,13].
CSF circulates over the ventricles, with a pulsatile and unidirectional flow along subarachnoid
spaces through three foramina: the lateral ventricles, the third and fourth ventricles and the
subarachnoid space. From the fourth ventricle, it enters the subarachnoid space between the arachnoid
and pia mater. CSF is reabsorbed mainly into venous blood across cranial and spinal arachnoid villi
and minimally via paraneural sheaths of nerves into lymphatics. CSF is renewed four to five times per
24 h in young adults. The reduction of the CSF turnover rate during ageing leads to accumulation of
catabolites in the brain and CSF observed in certain neurodegenerative diseases. CSF pressure varies
according to the age, from 3-4 mmHg in infants to 10–15 mmHg in adults, depending from a dynamic
equilibrium between CSF secretion and absorption, influenced by systolic pulse wave, respiratory
cycle, abdominal pressure, jugular venous pressure, state of arousal, physical effort and posture [14].
The analysis of cerebrospinal fluid through lumbar puncture (LP) procedures can provide information
on diagnosis and it may be therapeutic in certain conditions [15].
3. Biochemical Protection of the Brain: Blood Brain Barrier (BBB)
The brain is the best-perfused organ in the body, with over 100 billion capillaries, a total length of
400 miles and a total surface area of 20 m2. The vasculature of central nervous system supplies the
brain of nutrients and oxygen, but the presence of a protective BBB between the blood compartment
and the brain is an essential prerequisite to assure correct neuronal functioning of the brain [16].
The BBB develops during fetal life, but it is not yet entirely formed and shows unique properties
not present in the adult type [17]. Still, recent data have showed that intercellular tight junctions and
many of the influx and efflux transporters form already since embryonal and fetal life in the interfaces
between blood, brain and CSF [18,19]. However, these barrier mechanisms are more fragile with a
major susceptibility of the developing brain to drugs, toxins and pathological conditions (such as
inflammation, hypoxia, hyperbilirubinemia, exposure to environmental toxicants). Consequently, the
exposure to pharmacologically molecules or toxins during fetal and neonatal life may impair neuronal
division, migration, differentiation and synaptogenesis [20].
In the developed brain the areas of the brain without BBB are known as “circumventricular
organs”, including pineal body, subfornical organ, median eminence, neurohypophysis, area postrema,
vascular organ of the lamina terminalis [21].
The BBB provides a protective mechanism that helps to maintain a stable environment for the
brain, by highly selective regulation of the exchange of ions, nutrients, metabolites and potentially
toxic substances between blood and the brain [22].
The BBB is made by the endothelial cells of the brain capillaries, that are in continuous interactions
with astrocytes, pericytes and perivascular macrophages, forming the “neurovascular unit” (NVU) [23].
In brain capillaries, the endothelial cells are closely connected each other by tight junctions that fuse
brain capillary endothelia together into a continuous cellular layer (Figure 1). The tight junctions
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restrict the paracellular diffusion between the endothelial cells to ions and other polar solutes, blocking
penetration of macromolecules. In fact, only great lipid and non-polar solutes may passively diffuse
through the cell membrane and cross the endothelium. Conversely, the presence of solute carriers (SLCs)
allows the transport of many essential polar molecules, such as glucose, amino-acids and nucleosides,
into the CNS. Moreover, receptor-mediated transcytosis (RMT) can transport macromolecules such as
peptides and proteins, across the cerebral endothelium; positively charged macromolecules may be
transported across the endothelium through adsorptive-mediated transcytosis (AMT) [24].
Figure 1. Main characteristics of blood-brain barrier (BBB).
The passage of drugs through the BBB is influenced by several conditions: molecular weight
(large molecules do not easily pass through the BBB), ionization at physiological pH (molecules that
have a high electrical charge are slowed), liposolubility (low lipid-soluble molecules do not simply
penetrate into the brain) and protein binding [25].
Furthermore, the achievement of therapeutic concentration of drugs in CNS is complicated
by the presence of ATP-Binding Cassette (ABC) efflux transporters, a distinct set of efflux protein
localized on the BBB. These efflux transporters are neuroprotective, because they limit the brain entry
of neurotoxins; however, they could also restrict the entry of many therapeutics, contributing to CNS
pharmacoresistance [26,27].
In humans, P-gp is the best known multidrug resistance (MDR) transmembrane protein, involved
in ATP-dependent drug efflux pump, extruding several potentially toxic substances such as various
anticancer drugs [28,29]. In addition to P-gp, BCRP is also consider to have a major role in in the
control of molecular traffic across the endothelial cells and in drug efflux at the BBB [30]. Recently, in
their in vivo study Blakeley et al. have confirmed the direct involvement of BCRP in MTX transport
across the BBB, showing that the extrusion of MTX is significantly reduced in BCRP knockout model
compared with the wild type [31,32]. Both P-gp and BRCP are expressed early during embryonal
life; moreover, while P-gp level increases widely from the perinatal to adult stage, BCRP expression
remains stable during development [33,34].
Numerous CNS pathologies (such as stroke, trauma, infectious or inflammatory processes, HIV,
epilepsy, pain, lysosomal storage disease, brain tumors) involve BBB dysfunction, which can range
from mild and transient to chronic barrier breakdown [35].
The structure of tumor blood vessels in aggressive brain tumors (such as glioblastoma multiform)
is very different from normal blood vessels, including a high endothelial proliferation with widespread
infiltration of surrounding tissue. The loss of tight junction in the tumor endothelium leads to the
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disruption of BBB in the primary tumor site, but not in the infiltrative tumor areas, that are consequently
the most difficult lesions to treat. Treatment of primary tumors may be facilitated by the permeable
vessels, but not in the infiltrative tumor areas, were the BBB is provided of tight junctions [36,37].
Besides, the tumor vascular system maintains the other biological components of the BBB, such as
multidrug resistance-associated proteins. Consequently, many anti-cancer drugs are large, hydrophobic
and unable to easily go through the BBB, but they are also substrates for the MRD efflux pumps also
expressed by tumor vessels [38].
4. Failed Approaches
Over the years, various strategies have been developed to improve drug delivery into the brain,
bypassing the BBB [39]. Although they have failed in their purpose, as they are often not suitable for
the pediatric age due to their invasiveness, we describe them in order to address future investigations.
4.1. BBB Disruption (BBBD): Osmotic and Bradykinin Receptor-Mediated BBBD
In 1972 Rapaport et al. suggested for the first time that intra-arterial administration of hyperosmotic
solutions (such as mannitol which is the most widely used, but also arabinose, lactamide, saline, urea,
several radiographic contrast agents) may produce temporary shrinkage of endothelial cells, with
consequently opening of tight junctions for several hours, allowing in this time window the delivery of
chemotherapeutical agents [40].
BBBD seems to be temporary and reversible. Moreover, the non-selective opening of the BBB
allows an uncontrolled influx of low and high molecules (such as albumin and plasma proteins) into
the brain, with a high risk of seizures and reversible aphasia or hemiparesis [41].
The clinical benefit of osmotic BBBD has not been established for the treatment of less sensitive
tumors like gliomas, whereas it seems to increase survival in patients affected by primary lymphoma
and other chemo-sensitive tumors [42]. In their study Doolittle et al. established that intra-arterial
chemotherapy with an osmotic opening of the BBB results in a high degree of tumor response in patients
with chemotherapy-sensitive tumors (such as PNET, germ cell tumor and cancer metastasis) [43].
Osmotic BBBD has a more limited practice in children than in adult. In 2006 Hall et al. conducted
a study among eight patients (median age 11 years) with diffuse pontine glioma (DPG), treated with
monthly osmotic BBBD chemotherapy with a low toxicity profile and survival times longer than those
previously reported in other DPG series, concluding that further examination of this treatment for
pediatric patients with DPG or other malignant brain tumors was necessary [44].
An alternative attempt to osmotic BBBD is based on the use of an intra-carotid arterial infusion
of bradykinin which stimulates receptors on the BBB, inducing opening of tight junctions via
second messengers [45]. RMP-7 (cereport or lobradimil) is a bradykinin analogue with improved
systemic exposure, designed to induce the bradychinin B2 receptors expressed on the endothelial cells.
Lobradimil increases permeability of the BBB within minutes following the infusion, by separating
the tight junctions between the endothelial cells of the brain capillaries, with the restoration of BBB
within 20 to 60 min from the end of the infusion [46,47]. Lobradimil may be used in addition with a
chemotherapeutic agent like carboplatin, allowing an enhanced uptake of carboplatin into and near
the tumor area [48]. Warren et al. studied the combination of lobradimil and carboplatin in pediatric
patients with primary brain tumors in a phase II trial. Still, they demonstrate that the combination of
lobradimil and carboplatin is not able to improve the response rate and the time to disease progression
in childhood high-grade gliomas and brainstem gliomas [49]. Thus, future studies should further
define the biologic conditions in which this drug actually works and the chemical properties of the
drugs that enter into the brain because of lobradimil.
4.2. Intra-Arterial Chemotherapy (IA)
IA chemotherapy is a form of regional delivery to brain tumors, designed to enhance the
intra-tumor concentrations of a given drug, in comparison with the IV route. The rationale of IA
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chemotherapy consists of obtaining high local concentrations of a drug with a steep dose-antitumor
activity curve. In IA infusion chemotherapy is administered through a catheter which is inserted
into the femoral artery and ends in the carotid artery. This procedure may imply an increased risk
of periorbital pain, visual loss (up to 10% with carmustine), hearing loss (up to 15% with cisplatin),
seizures, confusion and neurocognitive deficits. The risk of these toxicity seems to be related to the
heterogeneous distribution of the drug through the various branches of the carotid artery, while
the incidence of neurological side effects is significantly improved since the use of novel selective
micro-catheters [50].
IA delivery of chemotherapy is well-established for the treatment of hepatocellular carcinoma
and retinoblastoma [51,52]. Over the years, several preclinical and clinical studies have demonstrated
that IA chemotherapy may have a potential therapeutic benefit for low- and high-grade gliomas and
cerebral lymphomas.
Not all drugs have the appropriate metabolism and pharmacokinetic profile for IA usage. The
Ra (Regional advantage) equation defines the pharmacologic advantage that a drug may have when
administered IA versus the IV route:
Ra = 1 + [Cltb × (total body clearance)/F (blood flow)]
Ra is maximized by a rapid total body clearance of the infused drug, which allows, after the “first
pass” (during the venous recirculation phase), to extract by the tumor tissue a relative smaller amount
of drug than the amount extracted during the “first pass” [53]. The drugs with the most appropriate
Ra for IA chemotherapy (ranked in descending order) are carmustine and other nitrosoureas, cisplatin,
carboplatin, etoposide and methotrexate [54]. However, a survival benefit for IA drug delivery, in
comparison with IV administration, has not been proven in phase III trials and further clinical studies
are required to determine the appropriate role for IA chemotherapy in the treatment of primary brain
tumors, especially in children [55].
4.3. Intracavitary Chemotherapy
Another strategy for circumventing the BBB is the intracavitary chemotherapy (IC), which consists
in the implantation of a biodegradable polymer wafer, chemotherapy-impregnated, into the brain or
tumor cavity at the time of surgery. This procedure allows obviating these problems, providing the local
sustained release of chemotherapeutic agents to the tumor site, prolonging local exposure with minimal
systemic toxicity. Gliadel wafers are biodegradable polymer loaded with BCNU (carmustine), which
has considerable systemic toxicity and a short half-life in serum [56]. Gliadel wafers are FDA-approved
treatment of new-diagnosed and recurrent adult glioblastoma. Their efficacy and safety have been
demonstrated in randomized controlled trials which showed that this approach may delay both clinical
and radiological progression, increasing the survival rate [57–59]. Moreover, their use is currently
controversial among neurosurgeons, due to the increased risk of complications, such has seizures,
edema, infection, CSF leaks, obstructive hydrocephalus (due to dislodgment of the wafer) [60–62].
In their study, Sardi et al. reported the cases of three pediatric patients with recurrent anaplastic
brain ependymoma, first treated with surgery, then followed by of intracavitary BCNU wafers (Gliadel)
implantation in combination with low-doses oral etoposide. Their approach was not effective for the
treatment of refractory anaplastic ependymoma. Further studies are necessary to define the potential
role of BCNU wafer implantation in the tumor bed after the first tumor resection in addition to
consolidated systemic chemotherapy in children with high-risk brain tumors [63].
5. Invasive Drug Delivery Directly in the CSF: Intrathecal Chemotherapy (IT)
The administration of antineoplastic drugs directly in the CSF allows to bypass the selective filter
of BBB, achieving significant concentrations of the antineoplastic agents in CSF, while reducing the
likelihood of systemic toxicity [64]. In fact, at relatively smaller doses, the CSF drug concentrations are
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more consistent with the IT route, for the smaller CSF volume than the blood compartment (140 vs.
3500 mL), for longer half-lives in CSF than in plasma and lastly for the almost negligible CSF drug
clearance by metabolic inactivation and/or protein binding [65]. IT drug delivery can be performed
through two methods: into the lumbar thecal sac by LP (intralumbar injection) or into lateral ventricles
trough a subcutaneous reservoir and ventricular catheter, called Ommaya reservoir (intraventricular
injection) [66].
5.1. Intraventricular Injection
The Ommaya reservoir is a subcutaneous device, with a catheter inserted in one of the lateral
ventricles of the brain, providing direct access to ventricular CSF [67]. Drugs are injected with a syringe
in the ventricular reservoir, after having extracted a CSF volume comparable to the volume of the
administered drug and followed by cleaning with about 2–4 mL of 0.9% sodium chloride solution [68].
This technique is indicated for patients that required prolonged treatments and when LP could
be difficult to perform. Additionally, the advantage of this approach is a more homogeneous drug
distribution and a higher drug concentration in the subarachnoid space compared with LP. Better
clinical results are achieved especially for the treatment of CNS leukemia or of neoplastic meningitis
due to solid tumors [69]. Conversely, it seems to have limited effectiveness for parenchymal masses,
because the concentrations of most drugs fall to insignificant levels at few millimeters from the
ependymal surface [70].
Moreover, the implantation of Ommaya reservoirs may cause long-term complications, including
catheter obstruction, hemorrhage and infections. Peyrl et al. analyzed their 20-year experience with
Ommaya reservoirs in 98 children with brain tumors, concluding that complications may be reduced
with specific training to all workers involved in implanting and accessing the device, with careful
attention to strict aseptic conditions [71]. Gerber et al. in their retrospective analysis of 31 consecutive
pediatric patients with Ommaya reservoirs, found infection as the most frequent complication. They
concluded that further prospective studies are demanded to evaluate preventive measures, such as the
administration of peri-operative antibiotics and the use of an antimicrobial coating of catheters [72].
5.2. Intralumbar Injection
LP is an invasive technique commonly used in pediatric oncology as a diagnostic procedure, but
also therapeutically, to inject medications directly into the subarachnoid space [73]. Patients can be in
lateral decubitus or sitting positions, which is the preferred position for infants and children [74]. The
lowest necessary CSF volume, usually 5–8 mL is extracted for analyses in children and adolescents,
2–3 mL in newborn and infants. Besides, when LP is conducted as therapeutically procedure, it is
recommended to slowly administrate the drug, approximately over 3 to 5 min, to reduce the risk of
subsequent headaches. Before IT administration it’s necessary to extract a CSF volume equivalent to
the volume of chemotherapy instilled; different authors have described injection of volumes ranging
from 5 mL to 15 mL [75].
Repeated LP are stressful and painful; therefore, pharmacological sedation is recommended in
pediatric patients. Maurizi et al. conducted 252 lumbar punctures under deep sedation with propofol
and ketamine in 25 children with ALL, achieving satisfactory sedation and analgesia care in all patients,
reducing the risk of traumatic LP and improving comfort and quality of life (QoL) [76].
After drug injection, it is recommended to stay at least 1 h supine, flat on the back on a 15–30 degree
incline with the feet elevated above the head (Trendelenburg position), to facilitate the penetration of
the drug in the brain ventricles, avoiding its prolonged presence in the spinal cord and consequently its
absorption through the venous vertebral plexus into the blood. In fact, the slow and unidirectional CSF
flow limits the distribution of the drug, which results in relatively low and variable concentration in the
ventricular CSF. Studies in animals have shown that ventricular levels of MTX at 1 h after intralumbar
injection were as much as 1000 higher in animals kept prone or in Trendelenburg position, compared
with CSF concentration in animals kept upright [77].
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LP may determine several complications, such as post-puncture headache, lower back pain, nerve
root irritation, infections or hemorrhages. Another disadvantage consists in the potential injection
or leaking of the drug into the subdural or epidural space, which seems to occur in about 10% of LP.
Additionally, delayed clearance of intrathecal chemotherapy may be observed in a lot of conditions
that interfere with CSF flow. In contrast, the patients with a ventriculo-peritoneal or ventriculo-atrial
shunt are at increased risk of a rapid clearance of the drug from the CSF space by the shunt, with an
inadequate drug exposure [78].
5.3. Pharmacokinetics and Toxicity of Standard Agents for IT Administration
Despite the presence of numerous systemically active drugs, only a few chemotherapeutic agents
are currently available for IT delivery in pediatric oncology, such as MTX, cytosine arabinoside (Ara-C),
corticosteroids, and thiotepa. More recently, some other antineoplastic agents are under evaluation for
IT administration. In Table 2 we summarize the chemical structures, relevant properties and clinical
uses of these pharmacological agents.
There are several antineoplastic drugs limited to systemic administration, such as melphalan,
chlorambucil, cisplatin, mitoxantrone, dactinomycin, mercaptopurine and vincristine [79]. Their
IT administration is extremely dangerous and usually life-threatening. In particular, vincristine is
very neurotoxic and if administered IT produces quickly and fatal ascending leptomeningitis and
ventriculitis, which require prompt CSF lavages to remove the drug [80–82].
As shown in Figure 2, CSF volume is age-related in infants and young children, because it increases
more rapidly than body surface area (BSA), reaching adult levels after the first three years of age. Thus,
IT chemotherapy in children is usually administered with age-related dosage and not based upon BSA,
to obtain an increased therapeutical effect, reducing neurotoxicity [83]. In Table 3 age-related dosage of
triple intrathecal (TIT) chemotherapy used in pediatric oncology are reported [84].
Figure 2. CSF volume compared to BSA in infants and young children. The CSF volume increases at a
more rapid rate than BSA, reaching adult volume after the first three years of age (adapted from Bleyer
et al. [83]).
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Table 2. Chemical structures, relevant properties and clinical use of antineoplastic agents indicated for IT use in pediatric oncology.
Name of Drug and Structure Chemical Formula Properties Indications for IT Use in Pediatric Oncology
Methotrexate (MTX)
C20H22N8O5
Molecular weight: 454.45 g/mol
MTX does not penetrate the BBB in therapeutic
amounts when given orally or parenterally. High
CSF concentrations of the drug may be achieved by
IT administration.
Acute lymphoblastic leukemia (ALL)
Advanced non-Hodgkin lymphomas (NHL)
CNS leukemia and lymphoma (prophylaxis)
Cytosine Arabinoside (Ara-C)
C9H13N3O5
Molecular weight: 243.22 g/mol
Only the use of high IV doses of Ara-C (>1 g/mq)
produces significant CSF level of Ara-C above 1
micromol/L, with increased risk of neurotoxicity
Acute myeloid leukemia
Acute lymphoblastic leukemia (ALL)
CNS leukemia and lymphoma (prophylaxis)
Hydrocortisone
C21H30O5
Molecular weight: 362.47 g/mol
Good penetration into the CSF compartment after
IV infusion CNS leukemia and lymphoma (prophylaxis)
Thiotepa
C6H12N3PS
Molecular Weight: 189.217 g/mol
Good penetration into the CSF compartment after
IV infusion
Hematopoietic stem cell transplant (HSCT) for
CNS malignancy
Busulfan
C6H14O6S2
Molecular Weight: 246.30 g/mol
Good penetration into the CSF compartment after
IV infusion
Leptomeningeal disease from recurrent or
progressive primary brain tumors
Topotecan
C23H23N3O5
Molecular Weight: 421.453 g/mol
Moderate penetration into the CSF (about 30%) after
IV infusion
CNS leukemia or lymphoma, relapsed or
refractory
6-Mercaptopurine (6-MP)
C5H4N4S
Molecular Weight: 152.175 g/mol
Poor penetration into the CSF compartment after IV
infusion
Acute lymphoblastic leukemia
Lymphoblastic lymphoma
Mafosfamide
C9H19Cl2N2O5PS2
Molecular Weight: 401.269 g/mol
Phase I trials showed that IV administration is
unacceptable due to severe local pain at the injection
site, thus mafosfamide is used through IT route
Leptomeningeal disease from recurrent or
progressive primary brain tumors
Rituximab * C6416H9874N1688O1987S44Molecular Weight: 143859.7 g/mol
Poor penetration into the CSF compartment after IV
infusion Recurrent lymphomatous meningitis
* Rituximab is a monoclonal antibody (macromolecule) and not a small molecule like the others.
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Table 3. Age-related dosage of TIT chemotherapy in children (adapted from Pinkel et al. [43]).
Age Methotrexate(MTX)
Cytosine Arabinoside
(Ara-C) Hydrocortisone
≥1 year and <2 years 8 16 8
≥2 years and <3 years 10 20 10
≥3 years 12 24 12
5.3.1. MTX
IT MTX has been used for over 50 years in pediatric oncology for the prevention and treatment of
CNS blast cell infiltration in acute leukemias and lymphomas, either as a single agent or in combination
with Ara-C and hydrocortisone, in the so called “triple intrathecal chemotherapy” [85].
The pharmacokinetics of IT MTX is different from systemic administration. Elimination of MTX
from the CSF is biphasic, with an initial elimination half-life (t1/2) of 4.5 h and a final t1/2 of 14 h. MTX
clearance is provided by CSF reabsorption, thus it mainly depends from CSF flow. In fact, MTX slowly
diffuses from CSF to the plasma compartment, therefore closely repeated IT infusions may behave as a
prolonged IV infusions, causing systemic toxicity [86].
Although, after intralumbar infusion, CSF concentration of MTX is about 100 times higher than
plasma, the CSF ventricular concentration reaches approximately only the 10% of the simultaneous
lumbar CSF concentration. Numerous studies warned that intraventricular administration of MTX
may provide higher and prolonged ventricular CSF concentration. Ventricular Ommaya reservoir
facilitates drug administration, giving repeated small intrathecal doses of MTX over an extended
period (for example 1 mg every 12 h for 6 doses). This “concentration times time (C × T) approach”
increases the duration of exposure of tumor cells to antineoplastic drug and avoids excessive peak
concentrations, simultaneously increasing the potential efficacy and decreasing toxicity [87,88].
The risk of neurotoxicity from IT MTX is augmented in the presence of obstructive hydrocephalus,
meningeal leukemia or leptomeningeal spread of solid tumors which may interfere with MTX CSF
clearance [89]. Potential MTX-neurotoxicity is generally categorized into three forms: acute, sub-acute,
chronic. The most frequent form is the acute one, which occurs several hours to few days after MTX IT
injection, potentially influenced both by dose and frequency of IT exposure. Acute toxicity presents
as a chemical aracnoiditis, with meningism, headache, nuchal rigidity, back pain, fever, and CSF
pleocytosis [90].
Rarely patients may develop a sub-acute toxicity within 2 or 3 weeks of MTX IT injection, probably
due to a persistent toxic drug concentration in the CSF, with the onset of reversible or irreversible
paraplegia, myelopathy or encephalopathy, characterized by limb weakness, ataxia, cranial nerve
palsies, visual impairment, seizures or coma [91].
A late and chronic neurotoxicity may occur months or even years after MTX IT treatment,
presenting with progressive demyelating leukoencephalopathy, with limb spasticity, dementia or coma.
The addiction of cranio-spinal irradiation or the simultaneous repeated administration of high-dose IV
MTX seem to enhance the risk of chronic MTX neurotoxicity [92].
Finally, an accidental MTX IT overdose is associated with an acute life-threatening toxicity,
which requires immediate rescue. Different approaches may be useful if promptly applied, such
as CSF drainage, ventricololumbar perfusion, systemic administration of high-dose leucovorin and
steroids, intrathecal instillations of carboxypeptidase-G2, which hydrolyzes MTX in an inactive
metabolite [93–96].
5.3.2. Cytosine Arabinoside (Ara-C) and DepoCyt
IT Ara-C is another effective agent primarily used in the treatment of CNS leukemia and lymphoma
for the prevention and treatment of CNS infiltration, alone or in TIT chemotherapy. As MTX IT, the
dosage of Ara-C IT is calculated according to age rather than BSA [97].
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Elimination of Ara-C from CSF is biphasic, with t1/2 of 1 h and 3.4 h. Following a single IT
Ara-C dose of 30 mg, a peak CSF concentration >2 µM/L is reached and it remains above 1 µM/L
during at least 24 h. Zimm et al., conducted a pharmacokinetic study in seven patients with leukemic
meningitis in complete remission, showing that a single dose of 30 mg of IT Ara-C may produces
CSF concentration of 1 µM/L, providing a 24-h coverage. As with intraventricular MTX, the “C × T
approach” may prolong the exposure to the Ara-C. Pharmacokinetics studies have demonstrated that
daily intraventricular administration of 30 mg of Ara-C for 3 consecutive days allows to maintain a
cytotoxic concentration for 72 h, compared to about 24 h after a single 70 mg dose [98].
IV Ara-C is rapidly eliminated from plasma through the enzyme cytidine deaminase, which
metabolize Ara-C into the inactive uracil arabinoside (Ara-U). Conversely, the conversion to Ara-U is
negligible after IT administration, because of the negligible concentration of the enzyme in CSF [99].
Thus, the clearance of Ara-C from CSF is about 0.42 mL/min (eight times lower than from plasma), a
value similar to the rate of CSF bulk flow (0.35 mL/min), suggesting that an irrelevant transfer rate
from CSF to plasma is possible.
After systemic administration of low dose Ara-C (such as 100 mg/mq) not significant CSF
concentrations may be observed, but the use of high IV doses of Ara-C (such as >1 g/mq) produces a
CSF level of Ara-C above 1 µM/L, with increased risk of unexpected neurotoxicity. The most observed
neurotoxicity after Ara-C IT is a chemical aracnoiditis, other common ones are seizures, transient
paraplegia, myelopathy and encephalopathy [100,101].
DTC 101 (DepoCyt) is a slow-release formulation developed to allow a prolonged exposure to
cytotoxic concentration, with a lower frequency of IT Ara-C administration. Ara-C is encapsulated in
multivescicular liposomes called DepoFoam, that gradually degrade, entering in the normal lipidic
pathway of the body [102]. After a single dose of IT DepoCyt, the terminal t1/2 was increased
approximately 40-fold versus conventional Ara-C (from 3.4 to about 141 h), ensuring cytotoxic
concentration of about 14 days with a single dose of 50 mg of IT DepoCyt [103].
In a phase I trial of IT DepoCyt in children with advanced meningeal malignancies, Bomgaars
et al. found a maximum-tolerated dose of 35 mg, when administered with dexamethasone with the
evidence of prolonged disease stabilization or response [104].
The toxicity profile of DepoCyte is similar to the conventional Ara-C. Chamberlain et al.
retrospectively analyzed the incidence of neurotoxicity after administration of DepoCyt in adult
patients with leptomeningeal metastasis, demonstrating that DepoCyt was generally well tolerated,
whereas serious treatment-related neurological complications (bacterial and chemical meningitis,
hydrocephalus, conus medullaris/cauda equina syndrome, decreased visual acuity, encephalopathy,
leukoencephalopathy, myelopathy, radiculopathy and seizures) occurred in about 12.5% of patients [105].
Further studies are required to assess safety and long-term toxicity of DepoCyt, especially in the
pediatric population.
5.3.3. Corticosteroids
The use of hydrocortisone in combination with MTX and Ara-C in TIT chemotherapy has been
showed to have an additive and synergic effect for prophylaxis and treatment of CNS leukemia and
lymphoma [106,107].
Currently, other corticosteroids are not licensed for IT chemotherapy in children, but
dexamethasone could be a potential candidate for IT administration. Non-human preclinical
studies demonstrated both dexamethasone and prednisolone are quickly cleared from CSF after
IT administration. Furthermore, after IV infusion dexamethasone shows higher free plasma levels
compared to prednisolone, due to a lower plasma protein binding (70% for dexamethasone compared
to 90% for prednisolone), resulting in greater penetration into the CSF compartment [108].
The neurotoxicity of IT corticosteroids has not been proved yet by controlled studies, although
several studies have described the potential development of psychiatric adverse effects, from depressive
syndromes to psychosis, caused by the use of IT corticosteroids [109].
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5.3.4. Thiotepa
Thiotepa is a lipid soluble alkylating agent available for IT administration, which doesn’t produce
a significant advantage versus systemic thiotepa. In fact, after IV infusion both thiotepa and its active
metabolite (TEPA) rapidly cross the BBB, so CSF and plasma exposure becomes almost equivalent. In
addition, thiotepa and TEPA quickly diffuse out of the CSF, because of their conspicuous CSF clearance,
which is nine times the rate of CSF flow [110,111].
IT thiotepa is proposed as a treatment of leptomeningeal metastases in children, but unfavorable
outcomes observed in a lot of studies suggest that intrathecal thiotepa adds little to standard
chemotherapy [112]. Martín Algarra et al. described two unexpected cases of severe polyneuropathy
and motor loss after IT thiotepa, combined with IT MTX, IT Ara-C and radiotherapy, indicating the
need for further toxicology research on IT thiotepa [113].
5.3.5. Investigational Agents for IT Administration
Some antineoplastic agents and monoclonal antibodies have been investigated for IT administration
in preclinical and phase I/II studies; still, their clinical use remains limited.
Oral 6-mercaptopurine (6-MP) is crucial for systemic maintenance therapy for ALL, but for the first
time in 1991 Adamson et al. performed a phase I/II study of IT 6-mercaptopurine (6-MP) administration
in pediatric patients with refractory meningeal leukemia. A 10-mg IT dose of 6-MP was administered
twice weekly for 4 weeks, obtaining complete responses in four out of nine patients, with no significant
toxicity [114].
Topotecan is a topoisomerase I inhibitor with anti-tumor activity against many adult and childhood
solid tumors. In preclinical and clinical studies, the CSF penetration of the active form of topotecan
was approximately 30% after systemic administration, without neurologic toxicity [115,116]. Potter et
al. conducted a phase II study to evaluate the response rate and safety of IT topotecan in children with
recurrent or refractory CNS leukemia or lymphoma, obtaining 38% of complete response, with mild to
moderate adverse events and reversible side effects [117].
Busulfan is an alkylating agent usually used as an oral formulation in high-dose chemotherapy
schedules for allogenic and autologous bone marrow transplantation in patients with leukemia and
solid tumors. A water-soluble microcrystalline formulation of Busulfan (Spartaject Busulfan) has
been found to be active in non-human neoplastic meningitis and safe following IT injection in adult
patients with leptomeningeal disease [118]. In their phase I trial, Gururangan et al. established that
IT Spartaject Busulfan was well tolerated in children with leptomeningeal disease from recurrent or
progressive primary brain tumors, estimating 13 mg as the maximum tolerated dose [119].
Mafosfamide is a cyclophosphamide analogue which spontaneously degrades to
4-hydroxy-cyclophosphamide, a derivative which doesn’t require hepatic microsomal activation for
antineoplastic activity. The effects of IT mafosfamide on various types of cancer cells were determined
during preclinical investigations and clinical trials [120]. In pediatric oncology IT mafosfamide has
been used safely for pediatric brain tumors with meningeal dissemination, prolonging remission of
the leptomeningeal disease [121]. Lastly, in 2012 the Pediatric Brain Consortium Study performed a
pilot study to investigate the feasibility of the addition of IT mafosfamide (14 mg) to a regimen of
concomitant multi-agent systemic chemotherapy followed by conformal radiotherapy for children
<3 years of age with newly diagnosed embryonal CNS tumors [122].
Rituximab is an anti-CD20 antibody added to chemotherapy regimens mostly for systemic B-cell
lymphoma, with improved efficacy and minimal side effects. Rituximab and the other monoclonal
antibodies have low penetration in CSF with heterogeneity in the distribution within the tumor. Thus,
their IT employ has been limited. In their study of patients with recurrent lymphomatous meningitis,
Chamberlain et al. showed that the combination of IT liposomal Ara-C and rituximab produced
modest palliative activity, without additional toxicity [123].
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6. Future Directions
In this section we show the most promising approaches currently in development for circumventing
BBB and improving brain drug delivery, with the hope to forward potential future direction in this
field, which may represent an example of personalized medicine.
6.1. Intranasal (INas) Drug Delivery
Intranasal drug delivery is emerging as a practical, safe and non-invasive method to bypass
the BBB and deliver a wide range of neurotherapeutic agents to the brain. This approach has been
primarily used to investigate therapeutic possibilities for neurological diseases (such as Alzheimer′s
disease, depression, migraine, schizophrenia, etc) [124,125].
In regard to brain tumor therapy, INas delivery has been little investigated so far, but published
results indicate interesting potential for this approach in treating CNS cancer. MTX, raltitrexed and
5-fluorouracil (5-FU) have all been shown to accumulate in the brain after INas delivery [126]. After
INas delivery 5-FU results in significantly greater brain exposure than IV infusion, however despite its
favorable pharmacokinetic profile, this therapeutic approach should be evaluated in preclinical brain
tumor models to assess efficacy [127,128].
6.2. Focused Ultrasound (FUS)—Mediated Drug Delivery
Focused ultrasound is an emerging and non-invasive method to transiently increase permeability
of the BBB [129]. In 2001, Hynynen et al. combined low power ultrasound with the delivery of
IV microbubble contrast agent. When the circulating microbubbles pass through the ultrasound
field, they oscillate at the frequency of the ultrasound, performing a stable cavitation [130]. Blood
vessels mechanically stimulated within the stable expansion and contraction of the microbubbles,
lead to transient and reproducible BBB opening, without long-term deficits in barrier function. The
microbubbles concentrate the ultrasound energy, significantly reducing the amount of ultrasound
pressure required to open the BBB and the risk of brain damage [131]. MRI is used for targeting
the brain in order to direct drugs to the brain region of interest. This would be advantageous for
chemotherapeutic treatment of brain tumors, limiting the access of antineoplastic drugs to the tumor
and its periphery and avoiding the remaining healthy brain tissue [132].
Several preclinical studies show efficacy of the delivery of anticancer drugs into the brain after FUS
induced BBB disruption, such as with doxorubicin [133,134], MTX [135], BCNU and epirubicin [136].
More investigation on the biological effects produced by FUS and its safety profile should be undertaken,
still preclinical encouraging outcomes indicate its potential translation in clinical application [137].
6.3. Convection Enhanced Delivery (CED)
Convection-enhanced delivery (CED) is a technique for circumventing BBB and delivering
therapeutics directly through the interstitial spaces of the CNS, using intraparenchymal microcatheters
with continuous positive-pressure infusion [138]. Many clinical studies using CED of chemotherapeutic
agents have been largely unsuccessful, showing which parameters should still be improved to obtain
an effective clinical application [139,140].
Recently however Souweidane et al. reported the first trial that demonstrates the efficacy and
safety of CED of a radioimmunotherapy agent targeting the glioma-associated B7-H3 antigen in children
with diffuse intrinsic pontine glioma (DIPG) who have previously received radiation therapy [141].
CED could be a useful strategy to control DIPG not only in the advanced stage, but also in the initial
stage, improving local disease control [142].
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7. Conclusions
BBBD, IA and intracavitary chemotherapy seem to have a restricted application in the treatment
of pediatric primary and metastatic CNS tumors, for their invasiveness and potentially serious
adverse effects.
Conversely, IT administration has been almost widely employed in the treatment of ALL and
lymphoma to avoid the neurotoxicity of cranial irradiation. Intralumbar administration is safe and
not painful if practiced with adequate deep sedation, whereas the implant of subcutaneous Ommaya
reservoirs allows the release of a higher and more homogeneous drug concentration in the arachnoids
space compared with intralumbar administration, avoiding stressful subsequent LP. However, Ommaya
reservoirs are correlated with an elevated risk of infections or obstructive complications, which clinicians
must try to prevent.
IT administration in pediatric oncology is substantially limited to MTX, Ara-C and hydrocortisone,
alone or in TIT, because of the extreme neurotoxicity of many other systemic antineoplastic agents,
which if accidentally given by IT are described as usually fatal.
Moreover, the IT dose of MTX, Ara-C and hydrocortisone are age-related and not BSA-related,
to reduce the incidence of neurotoxic side effects, enhancing their effectiveness, especially in
younger children.
Finally, several antineoplastic agents and monoclonal antibodies have been investigated for IT
administration in preclinical and phase I/II studies, but further studies are required to improve their
clinical use.
Future clinical studies should investigate the new promising approaches currently in development
to improve brain drug delivery in pediatric primary and metastatic CNS tumors, such as INas or
FUS-mediated drug delivery and CED.
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